相似文献
1
Improving quality and diffusing best practices: the case of schizophrenia.
Health Aff (Millwood). 2009 May-Jun;28(3):701-12. doi: 10.1377/hlthaff.28.3.701.
2
What explains the diffusion of treatments for mental illness?
Am J Psychiatry. 2008 Nov;165(11):1385-92. doi: 10.1176/appi.ajp.2008.08030334.
3
[Is a jolt passing through oncology?].
MMW Fortschr Med. 2006 May 25;148(21):13-4.
4
Improving mental health treatments through comparative effectiveness research.
Health Aff (Millwood). 2009 May-Jun;28(3):783-91. doi: 10.1377/hlthaff.28.3.783.
5
Quality of care in mental health: the case of schizophrenia.
Health Aff (Millwood). 1999 Sep-Oct;18(5):52-65. doi: 10.1377/hlthaff.18.5.52.
6
Quality assurance in Taiwan, the Republic of China.
Int J Qual Health Care. 1996 Feb;8(1):75-82. doi: 10.1093/intqhc/8.1.75.
7
The chronic psychiatric patient: problems, promises and perspectives, past, present and future.
Acta Psychiatr Scand Suppl. 2006(429):101-8. doi: 10.1111/j.1600-0447.2005.00726.x.
8
Infinite needs--finite resources: the future of healthcare.
Camb Q Healthc Ethics. 1994 Winter;3(1):83-98.
9
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.
Schizophr Bull. 2009 Sep;35(5):931-6. doi: 10.1093/schbul/sbn019. Epub 2008 Apr 2.
10
Incompatibility of capitation and government grant-in-aid programs.
Psychiatr Serv. 1996 Aug;47(8):795-6, 801. doi: 10.1176/ps.47.8.795.
引用本文的文献
1
Estimating racial and ethnic healthcare quality disparities using exploratory item response theory and latent class item response theory models.
J R Stat Soc Ser A Stat Soc. 2025 Apr 1. doi: 10.1093/jrsssa/qnaf033.
2
Race and Ethnicity and Diffusion of Telemedicine in Medicaid for Schizophrenia Care After Onset of the COVID-19 Pandemic.
JAMA Netw Open. 2025 Jan 2;8(1):e2454776. doi: 10.1001/jamanetworkopen.2024.54776.
3
Racial-Ethnic Disparities in Quality of Care Among Medicaid Beneficiaries With Schizophrenia.
Psychiatr Serv. 2024 Oct 1;75(10):969-978. doi: 10.1176/appi.ps.20230564. Epub 2024 Jun 12.
4
Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.
Schizophr Res. 2024 Feb;264:494-501. doi: 10.1016/j.schres.2024.01.028. Epub 2024 Jan 28.
5
Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations.
Front Pharmacol. 2023 May 22;14:1140969. doi: 10.3389/fphar.2023.1140969. eCollection 2023.
6
Statistical Approaches for Quantifying the Quality of Neurosurgical Care.
World Neurosurg. 2022 May;161:331-342.e1. doi: 10.1016/j.wneu.2022.01.047.
7
Customizing Early Intervention Treatment for Psychosis in the UTHealth - Harris County Psychiatric Center.
Inquiry. 2021 Jan-Dec;58:469580211049030. doi: 10.1177/00469580211049030.
8
Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults.
Adm Policy Ment Health. 2022 Jan;49(1):59-70. doi: 10.1007/s10488-021-01141-7. Epub 2021 May 19.
9
Neutrophil fluorescence in clozapine users is attributable to a 14kDa secretable protein.
Pharmacol Res Perspect. 2020 Oct;8(5):e00627. doi: 10.1002/prp2.627.
10
Does mental health staffing level affect antipsychotic prescribing? Analysis of Italian national statistics.
PLoS One. 2018 Feb 21;13(2):e0193216. doi: 10.1371/journal.pone.0193216. eCollection 2018.
本文引用的文献
1
Dual eligibles with mental disorders and Medicare part D: how are they faring?
Health Aff (Millwood). 2009 May-Jun;28(3):746-59. doi: 10.1377/hlthaff.28.3.746.
2
Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
N Engl J Med. 2008 Nov 6;359(19):1977-81. doi: 10.1056/NEJMp0806862.
3
What explains the diffusion of treatments for mental illness?
Am J Psychiatry. 2008 Nov;165(11):1385-92. doi: 10.1176/appi.ajp.2008.08030334.
4
Key factors for implementing supported employment.
Psychiatr Serv. 2008 Aug;59(8):886-92. doi: 10.1176/ps.2008.59.8.886.
5
The "3T's" road map to transform US health care: the "how" of high-quality care.
JAMA. 2008 May 21;299(19):2319-21. doi: 10.1001/jama.299.19.2319.
6
Lessons to take home from CATIE.
Psychiatr Serv. 2008 May;59(5):523-5. doi: 10.1176/ps.2008.59.5.523.
7
Policy toward second-generation antipsychotic drugs: a cautionary note.
Psychiatr Serv. 2008 May;59(5):521-2. doi: 10.1176/ps.2008.59.5.521.
8
Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
Psychiatr Serv. 2008 May;59(5):515-20. doi: 10.1176/ps.2008.59.5.515.
9
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
Schizophr Bull. 2009 Mar;35(2):443-57. doi: 10.1093/schbul/sbn018. Epub 2008 Apr 15.
10
QUALITY-CONSTANT "PRICES" FOR THE ONGOING TREATMENT OF SCHIZOPHRENIA: AN EXPLORATORY STUDY*.
Q Rev Econ Finance. 2004 Jul;44(3):390-409. doi: 10.1016/j.qref.2004.05.003.
Zotero 插件